Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, RareCyte is raising $22,156,736.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Joe Victor played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RareCyte

RareCyte is a company focused on characterizing and isolating rare cells from blood. We develop innovative products for applications in life science, pathology and clinical research as well as drug development and diagnostics. Our tools and solutions help answer difficult questions related to cancer, prenatal health, and infectious disease. RareCyte’s unique technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis.

To learn more about RareCyte, visit http://rarecyte.com/

Contact:
Joe Victor, Chief Executive Officer
855-727-3298
jvictor@rarecyte.com
https://www.linkedin.com/in/joevictor/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved